Structural Renal Changes in Obesity and Diabetes

Seminars in Nephrology

Volumn 33, Issue 1, 2013, Pages 23-33

  Amann, Kerstin ^a   Benz, Kerstin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Classification; Diabetic nephropathy; Kidney; Metabolic syndrome; Morphology; Ob FSGS; Obesity; Primary (idiopathic) FSGS

Indexed keywords

ADIPONECTIN; ALBUMIN; ALDOSTERONE; ALPHA ACTININ 4; ALPHA INTERFERON; ANABOLIC AGENT; ANGIOTENSIN; BETA INTERFERON; CALCINEURIN INHIBITOR; DIAMORPHINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; LEPTIN; LIPID; LITHIUM; NEPHRIN; PAMIDRONIC ACID; PHOSPHOLIPASE C; PHOSPHOLIPASE C EPSILON 1; PODOCIN; RAPAMYCIN; RENIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; WT1 PROTEIN;

ARTICLE; BARIATRIC SURGERY; BODY MASS; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULOPATHY; GLOMERULUS FILTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN PARVOVIRUS B19; HYPERLEPTINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MICROALBUMINURIA; NEPHRON; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIMIAN VIRUS 40; WEIGHT REDUCTION;

DIABETIC NEPHROPATHIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; OBESITY; PROTEINURIA;

EID: 84873199032     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.003     Document Type: Article

References (88)

1. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., Go A.S. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
2. Iseki K., Ikemiya Y., Kinjo K., Inoue T., Iseki C., Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004, 65:1870-1876.
3. Hitzenberger K. A report on metabolism in vascular hypertension. Wiener Archiv Innere Med 1921, 2:189-199.
4. Kylin E. Hypertension-hyperglycemia-hyperuricemia. Zentralblatt Innere Med 1923, 44:105-120.
5. Preble W. Observations on one thousand cases. Boston Med Surg J 1923, 188:617-621.
6. Gonzalez E., Gutierrez E., Morales E., Hernandez E., Andres A., Bello I., et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int 2005, 68:263-270.
7. Praga M., Hernandez E., Morales E., Campos A.P., Valero M.A., Martinez M.A., et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001, 16:1790-1798.
8. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002, 73:70-74.
9. Gross M.L., Amann K., Ritz E. Nephron number and renal risk in hypertension and diabetes. J Am Soc Nephrol 2005, 16(Suppl 1):S27-S29.
10. Ritz E., Koleganova N., Piecha G. Is there an obesity-metabolic syndrome related glomerulopathy?. Curr Opin Nephrol Hypertens 2011, 20:44-49.
11. Srivastava T. Nondiabetic consequences of obesity on kidney. Pediatr Nephrol 2006, 21:463-470.
12. Chen H.M., Li S.J., Chen H.P., Wang Q.W., Li L.S., Liu Z.H. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008, 52:58-65.
13. Nair R. Focal segmental glomerulosclerosis: cellular variant and beyond. Kidney Int 2006, 70:1676-1678.
14. Wei C., El Hindi S., Li J., Fornoni A., Goes N., Sageshima J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17:952-960.
15. Mele C., Iatropoulos P., Donadelli R., Calabria A., Maranta R., Cassis P., et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011, 365:295-306.
16. Deegens J.K., Dijkman H.B., Borm G.F., Steenbergen E.J., van den Berg J.G., Weening J.J., et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008, 74:1568-1576.
17. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23:117-134.
18. Stokes M.B., Valeri A.M., Markowitz G.S., D'Agati V.D. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006, 70:1783-1792.
19. Chun M.J., Korbet S.M., Schwartz M.M., Lewis E.J. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004, 15:2169-2177.
20. Deegens J.K., Steenbergen E.J., Borm G.F., Wetzels J.F. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population-epidemiology and outcome. Nephrol Dial Transplant 2008, 23:186-192.
21. Thomas D.B., Franceschini N., Hogan S.L., Ten Holder S., Jennette C.E., Falk R.J., et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006, 69:920-926.
22. Korbet S.M., Schwartz M.M., Lewis E.J. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994, 23:773-783.
23. Weisinger J.R., Kempson R.L., Eldridge F.L., Swenson R.S. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974, 81:440-447.
24. Cohen A.H. Massive obesity and the kidney. A morphologic and statistical study. Am J Pathol 1975, 81:117-130.
25. Jennette J.C., Charles L., Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis 1987, 10:470-472.
26. Kasiske B.L., Crosson J.T. Renal disease in patients with massive obesity. Arch Intern Med 1986, 146:1105-1109.
27. Warnke R.A., Kempson R.L. The nephrotic syndrome in massive obesity: a study by light, immunofluorescence, and electron microscopy. Arch Pathol Lab Med 1978, 102:431-438.
28. Verani R.R. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992, 20:629-634.
29. Bailey R.R., Lynn K.L., Burry A.F., Drennan C. Proteinuria, glomerulomegaly and focal glomerulosclerosis in a grossly obese man with obstructive sleep apnea syndrome. Aust N Z J Med 1989, 19:473-474.
30. Wesson D.E., Kurtzman N.A., Frommer J.P. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985, 40:235-237.
31. Kambham N., Markowitz G.S., Valeri A.M., Lin J., D'Agati V.D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498-1509.
32. Chen H.M., Liu Z.H., Zeng C.H., Li S.J., Wang Q.W., Li L.S. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006, 48:772-779.
33. Wu Y., Liu Z., Xiang Z., Zeng C., Chen Z., Ma X., et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006, 147:44-50.
34. Chagnac A., Weinstein T., Korzets A., Ramadan E., Hirsch J., Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000, 278:F817-F822.
35. Tomaszewski M., Charchar F.J., Maric C., McClure J., Crawford L., Grzeszczak W., et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007, 71:816-821.
36. Bosma R.J., van der Heide J.J., Oosterop E.J., de Jong P.E., Navis G. Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 2004, 65:259-265.
37. D'Agati V.D., Markowitz G.S. Supersized kidneys: lessons from the preclinical obese kidney. Kidney Int 2008, 73:909-910.
38. Krikken J.A., Lely A.T., Bakker S.J., Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007, 71:260-265.
39. Ingelfinger J.R. Is microanatomy destiny. N Engl J Med 2003, 348:99-100.
40. Saxena A.B., Myers B.D., Derby G., Blouch K.L., Yan J., Ho B., et al. Adaptive hyperfiltration in the aging kidney after contralateral nephrectomy. Am J Physiol Renal Physiol 2006, 291:F629-F634.
41. Brenner B.M., Garcia D.L., Anderson S. Glomeruli and blood pressure. Less of one, more the other?. Am J Hypertens 1988, 1:335-347.
42. Brenner B.M., Lawler E.V., Mackenzie H.S. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996, 49:1774-1777.
43. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005, 20:2594-2597.
44. Dengel D.R., Goldberg A.P., Mayuga R.S., Kairis G.M., Weir M.R. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 1996, 28:127-132.
45. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
46. Shibata S., Nagase M., Yoshida S., Kawarazaki W., Kurihara H., Tanaka H., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14:1370-1376.
47. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
48. Nagase M., Yoshida S., Shibata S., Nagase T., Gotoda T., Ando K., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006, 17:3438-3446.
49. Sharma K., Ramachandrarao S., Qiu G., Usui H.K., Zhu Y., Dunn S.R., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118:1645-1656.
50. Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010, 21:406-412.
51. Shen Y.Y., Peake P.W., Charlesworth J.A. Review article: adiponectin: its role in kidney disease. Nephrology (Carlton) 2008, 13:528-534.
52. Zoccali C., Mallamaci F., Panuccio V., Tripepi G., Cutrupi S., Parlongo S., et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kid Int Suppl 2003, 84:S98-S102.
53. Saraheimo M., Forsblom C., Fagerudd J., Teppo A.M., Pettersson-Fernholm K., Frystyk J., et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005, 28:1410-1414.
54. Afshinnia F., Wilt T.J., Duval S., Esmaeili A., Ibrahim H.N. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010, 25:1173-1183.
55. Morales E., Valero M.A., Leon M., Hernandez E., Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41:319-327.
56. Georgaki-Angelaki H., Stergiou N., Manolaki N., Nakopoulou L., Syriopoulou V.P., Roma-Giannikou E. Histological deterioration of obesity-related glomerulopathy despite the loss of proteinuria with weight reduction. Pediatr Nephrol 2010, 25:1573-1574.
57. Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003, 14:1480-1486.
58. Alexander J.W., Goodman H.R., Hawver L.R., Cardi M.A. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis 2009, 5:237-241.
59. Agrawal V., Khan I., Rai B., Krause K.R., Chengelis D.L., Zalesin K.C., et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol 2008, 70:194-202.
60. Fowler S.M., Kon V., Ma L., Richards W.O., Fogo A.B., Hunley T.E. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol 2009, 24:851-855.
61. Bayliss G., Weinrauch L.A., D'Elia J.A. D'EliaPathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 2012, 12:440-446.
62. Groop P.H., Thomas M.C., Moran J.L., Waden J., Thorn L.M., Makinen V.P., et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009, 58:1651-1658.
63. Tang S.C. Diabetic nephropathy: a global and growing threat. Hong Kong Med J 2010, 16:244-245.
64. Osterby R., Hartmann A., Nyengaard J.R., Bangstad H.J. Development of renal structural lesions in type-1 diabetic patients with microalbuminuria. Observations by light microscopy in 8-year follow-up biopsies. Virchows Arch 2002, 440:94-101.
65. Osterby R., Tapia J., Nyberg G., Tencer J., Willner J., Rippe B., et al. Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 2001, 109:751-761.
66. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008, 4:444-452.
67. Jauregui A., Mintz D.H., Mundel P., Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009, 18:539-545.
68. Lin S., Sahai A., Chugh S.S., Pan X., Wallner E.I., Danesh F.R., et al. High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway. J Biol Chem 2002, 277:41725-41735.
69. Najafian B., Alpers C.E., Fogo A.B. Pathology of human diabetic nephropathy. Contrib Nephrol 2011, 170:36-47.
70. Saito Y., Kida H., Takeda S., Yoshimura M., Yokoyama H., Koshino Y., et al. Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int 1988, 34:389-396.
71. Stout L.C., Kumar S., Whorton E.B. Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. Hum Pathol 1993, 24:77-89.
72. Chuang P.Y., Dai Y., Liu R., He H., Kretzler M., Jim B., et al. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011, 6:e23566.
73. Isermann B., Vinnikov I.A., Madhusudhan T., Herzog S., Kashif M., Blautzik J., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
74. Susztak K., Raff A.C., Schiffer M., Bottinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
75. Wolf G., Chen S., Ziyadeh F.N. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005, 54:1626-1634.
76. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
77. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Rennke H.G., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
78. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Ebihara I., et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000, 20:175-179.
79. Lewko B., Stepinski J. Hyperglycemia and mechanical stress: targeting the renal podocyte. J Cell Physiol 2009, 221:288-295.
80. Gross M.L., El-Shakmak A., Szabo A., Koch A., Kuhlmann A., Munter K., et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46:856-868.
81. Welsh G.I., Coward R.J. Podocytes, glucose and insulin. Curr Opin Nephrol Hypertens 2010, 19:379-384.
82. Brezniceanu M.L., Liu F., Wei C.C., Tran S., Sachetelli S., Zhang S.L., et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007, 71:912-923.
83. Bagby S.P. Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity. Kidney Int 2007, 71:1199-1202.
84. Fioretto P., Sutherland D.E., Najafian B., Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006, 69:907-912.
85. Bjorn S.F., Bangstad H.J., Hanssen K.F., Nyberg G., Walker J.D., Viberti G.C., et al. Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 1995, 38:1197-1204.
86. White K.E., Bilous R.W. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004, 19:1437-1440.
87. Tervaert T.W., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B., et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010, 21:556-563.
88. D'Agati V.D., Kaske F.J., Falk R.J. Focal segmental glomerulosclerosis. N Engl J Med 2011, 365:2398-2411.